Global Patent Index - EP 1037630 A2

EP 1037630 A2 2000-09-27 - METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS

Title (en)

METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS

Title (de)

METHODEN ZUR BEHANDLUNG VON MIT APOPTOSE ZUSAMMENHÄNGENDEN KRANKHEITEN DURCH N-HETEROCYCLISCHE GLYOXYL AMIDE VERBINDUNGEN

Title (fr)

METHODE DE TRAITEMENT DES TROUBLES LIES A L'APOPTOSE AU MOYEN DE COMPOSES DE GLYOXYLAMIDE N-HETEROCYCLIQUES

Publication

EP 1037630 A2 (EN)

Application

EP 98951749 A

Priority

  • JP 9805042 W
  • JP 9704104 W

Abstract (en)

[origin: WO9924026A2] A method or composition is disclosed for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds.

IPC 1-7 (main, further and additional classification)

A61K 31/40

IPC 8 full level (invention and additional information)

C07D 471/04 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/437 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01); C07D 209/18 (2006.01)

CPC (invention and additional information)

A61K 31/404 (2013.01); A61K 31/437 (2013.01)

Citation (search report)

See references of WO 9924026A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9924026 A2 19990520; WO 9924026 A3 19990715; AU 9763098 A 19990531; CA 2308269 A1 19990520; EP 1037630 A2 20000927; JP 2003522720 A 20030729; WO 9924033 A1 19990520

INPADOC legal status


2005-12-07 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20050601

2002-03-27 [17Q] FIRST EXAMINATION REPORT

- Ref Legal Event Code: 17Q

- Effective date: 20020206

2000-09-27 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20000609

2000-09-27 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE